<DOC>
	<DOCNO>NCT00631631</DOCNO>
	<brief_summary>The purpose study collect information regard safety tolerability mifamurtide ( liposomal muramyl tripeptide phosphatidyl ethanolamine ; L-MTP-PE ) .</brief_summary>
	<brief_title>Mifamurtide ( L-MTP-PE ) High-Risk Osteosarcoma</brief_title>
	<detailed_description>The drug test study call mifamurtide ( L-MTP-PE ; liposomal muramyl tripeptide phosphatidyl ethanolamine ) . Mifamurtide use treat people osteosarcoma , form cancer . This patient-access study look adverse event , disease progression , overall survival study participant . The study enrol 205 patient , 204 treat mifamurtide intravenously dose 2 mg/m2 twice weekly ( least 3 day apart ) 12 week , weekly additional 24 week , total 48 dos 36 week ( follow surgery primary metastatic disease ) . This study conduct United States . Participants could receive treatment 9 month . This study previously mis-categorized interventional study .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Mifamurtide</mesh_term>
	<mesh_term>Acetylmuramyl-Alanyl-Isoglutamine</mesh_term>
	<criteria>1 . Had sign inform consent/assent . Voluntary participation pharmacokinetic portion compassionate access protocol include informed consent require compassionate use participation . 2 . Had diagnosis high grade osteosarcoma relapse recurrent disease , locally metastatic , disease completely resectable unable complete recommend chemotherapy due toxicity : relapse , recurrence local metastatic ; unable standard surgical resection ; abbreviate chemotherapy regimen secondary toxicity ( e.g . hypophosphatemia ifosfamide , cardiotoxicity doxorubicin , renal dysfunction methotrexate , ifosfamide , cisplatin . ) 3 . Aged 2 ≤ 50 year . 4 . Had adequate hematopoietic function demonstrate : 1 ) Absolute Neutrophil Count ( ANC ) &gt; 750/microL ; Hemoglobin ( Hb ) &gt; 8 g/dL ; Platelets &gt; 30,000/microL . 5 . Had adequate hepatic function document 1 ) ALT &lt; 2.5 x upper limit normal ( ULN ) age ; 2 ) total bilirubin ≤ 1.5 x ULN age . 6 . Had adequate renal function demonstrate : 1 ) Creatinine clearance radioisotope glomerular filtration rate &gt; 70 mL/min/1.73 m^2 ; OR , 2 ) Serum creatinine ≤ 2x ULN age . 7 . Had absence concurrent active acute infection ( i.e. , afebrile ) . 8 . In female child bear potential ( menopausal 12 month previous surgical sterilization ) , negative pregnancy test . All sexually active participant use effective mean contraception . Such mean include oral contraceptive , Lupron Depot , DepoProvera , condom diaphragm spermicidal jelly . 9 . Performance status : Lansky 50100 % ( ≤ 16 year age ) ; OR , Eastern Cooperative Oncology Group ( ECOG ) 02 Karnofsky 50100 % ( &gt; 16 year age ) . 1 . Had chronic use corticosteroid immunosuppressive agent . 2 . Was pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>